Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-27T11:00:16.240Z Has data issue: false hasContentIssue false
  • English
  • Français

INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA

Published online by Cambridge University Press:  24 April 2017

Tomas Tesar ,
Adam Hloska ,
Martin Wawruch ,
Lubica Lehocka ,
Miroslava Snopkova  and
Lucia Masarykova
Tomas Tesar
Affiliation:
Department of Organization and Management in Pharmacy, Faculty of Pharmacy, Comenius University in Bratislavatesar@fpharm.uniba.sk
Adam Hloska
Affiliation:
Department of Pharmacology, Jessenius Faculty of Medicine, Comenius University in Bratislava
Martin Wawruch
Affiliation:
Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University in Bratislava
Lubica Lehocka
Affiliation:
Department of Organization and Management in Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava
Miroslava Snopkova
Affiliation:
Department of Organization and Management in Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava
Lucia Masarykova
Affiliation:
Department of Organization and Management in Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of our study was to describe approaches to health technology assessment (HTA) for medicines in the Slovak healthcare system and the related decision-making processes concerning reimbursement for medicines.

Methods: Analysis of the Slovak legislative framework related to HTA and the reimbursement process for medicines was performed. Additionally, current practices of the Working Group for Pharmacoeconomics, Clinical Outcomes and Health Technology Assessment of the Slovak Ministry of Health were evaluated.

Results: In Slovakia, there is always at least one treatment available in each determined therapeutic class with no co-payment. HTA is becoming an established method for the evaluation of cost-effectiveness of medicines in Slovak healthcare policy. The majority of decision makers within Slovakia support the idea of increased use of and the quality and efficiency of HTA methods. However, it is crucial to overcome several practical barriers to facilitate progress in the field of HTA in the Slovak Republic.

Conclusions: It can be seen that participation within the European Network for Health Technology Assessment (EUnetHTA JA 2 and EUnetHTA JA 3 projects) has significantly improved the quality of the process of HTA in Slovakia. Further legislative activities in this field are required due to the approved strategy for European Union cooperation on HTA.

Keywords

Technology assessmentBiomedicalDecision makingInsuranceHealthReimbursementHealth policySlovakia
Type
Theme Submissions
Information
International Journal of Technology Assessment in Health Care , Volume 33 , Issue 3: Theme: HTA in Central-Eastern-Southern Europe , 2017 , pp. 345 - 349
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Health Care Surveillance Authority. [Report on the status of provision of public health insurance during 2015] Spr´va o stave vykonávania verejného zdravotnŕho poistenia za rok 2015. Úrad pre dohľad nad zdravotnou starostlivosťou Vestník 11/2016;(11):[1-74 pp.]. http://www.udzs-sk.sk/documents/14214/19424/VE_10_2015_Sprava_VZP_2014.pdf/c2a32c3e-a50b-404f-941f-4a3fe189083f (accessed November 7, 2016).Google Scholar
2. Szalay, T, Pažitný, P, Szalayová, A, et al. Slovakia Health system review. Health systems in transition 2011;13 (2):[1-200 pp.]. http://www.euro.who.int/__data/assets/pdf_file/0004/140593/e94972.pdf (accessed November 7, 2016).Google ScholarPubMed
3. Barnieh, L, Manns, B, Harris, A, et al. A synthesis of drug reimbursement decision-making processes in Organisation for Economic Co-operation and Development countries. Value Health. 2014;17:98-108.CrossRefGoogle ScholarPubMed
4. Kaló, Z, Docteur, E, Moïse, P. Pharmaceutical pricing and reimbursement policies in Slovakia. OECD health working papers. Paris, France: OECD, Head of Publications Service; 2008 Feb 28. Report No.: DELSA/HEA/WD/HWP(2008)1.Google Scholar
5. [Act No. 363/2011 Coll. on the scope and conditions of payments for medicines, medical devices and dietetic foods from public health insurance and amending certain acts, as amended] Zákon č. 363/2011 Z. z. o rozsahu a podmienkach úhrady liekov, zdravotníckych pomôcok a dietetických potravín na základe verejného zdravotného poistenia a o zmene a doplnení niektorých zákonov, (2011). http://www.zakonypreludi.sk/zz/2011-363 (accessed November 7, 2016).Google Scholar
6. [Decree No. 422/2011 of the Ministry of Health of the Slovak Republic on the details of the pharmacoeconomic analysis of medicine] Vyhláška č. 422/2011 MZ SR o podrobnostiach farmako-ekonomického rozboru lieku, (2011). http://www.zakonypreludi.sk/zz/2011-422 (accessed November 7, 2016).Google Scholar
7. Tesar, T. Health technology assessment in reimbursement policy of the Slovak Republic. J Health Policy Outcomes Res. 2012;2012:21-23.Google Scholar
8. Ministry of Health of the Slovak Republic. [Methodical guidance for the completion of pharmacoeconomic analysis of a drug, health-economic analysis of a medical device and health-economic analysis of dietetic food] Metodická pomôcka pre vykonávanie farmako-ekonomického rozboru lieku, medicínsko-ekonomického rozboru zdravotníckej pomôcky a medicínsko-ekonomického rozboru dietetickej potraviny. Bratislava: Ministry of Health of the Slovak Republic; (2008). http://www.health.gov.sk/?farmako-ekonomicky-rozbor-lieku (accessed November 7, 2016).Google Scholar
9. Van Wilder, P, Mabilia, V, Kuipers Cavaco, Y, McGuinn, J. Towards a harmonised EU assessment of the added therapeutic value of medicines [Study of the ENVI Committee]. European Uninon: Policy Department A: Economic and scientific policy. European Parliament; (2015). http://www.europarl.europa.eu/RegData/etudes/STUD/2015/542219/IPOL_STU(2015)542219_EN.pdf (accessed November 7, 2016).Google Scholar